Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Matinas BioPharma Holdings, Inc. (MTNB)
|
Add to portfolio |
|
|
|
| Price: |
$0.97
| | Metrics |
| OS: |
217.3
|
M
| |
|
|
| Market cap: |
$211
|
M
| |
|
|
|
Net cash:
|
$22.5
|
M
| |
$0.10
|
per share
|
|
EV:
|
$188
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($27.0)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 3.2 | 0.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 |
| Revenue growth | 9560.6% | -79.2% | 76.3% | -25.0% | -20.0% | | -100.0% | |
| Cost of goods sold | 0.0 | 24.8 | 24.4 | 19.0 | 0.0 | 16.7 | 0.0 | 0.0 |
| Gross profit | 3.2 | -24.7 | -24.2 | -18.9 | 0.1 | -16.5 | 0.0 | 0.2 |
| Gross margin | 100.0% | -74954.5% | -15288.4% | -21067.4% | 100.0% | -11024.6% | | 100.0% |
| Research and development | 16.7 | 14.6 | 14.4 | 11.2 | 6.8 | 9.0 | 3.9 | 5.3 |
| General and administrative | 11.1 | 10.3 | 10.3 | 8.1 | 8.0 | 7.6 | 4.3 | 4.8 |
| EBIT | -24.6 | -24.7 | -24.2 | -18.9 | -14.6 | -16.5 | -8.3 | -9.9 |
| EBIT margin | -771.3% | -74954.5% | -15288.4% | -21067.4% | -12230.9% | -11024.6% | | -5096.0% |
| Pre-tax income | -21.0 | -23.3 | -22.4 | -17.4 | -13.6 | -15.1 | -7.6 | -9.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.4 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | | 0.0% | 0.0% |
| Net income | -21.0 | -23.7 | -23.2 | -18.3 | -15.0 | -32.8 | -12.0 | -9.1 |
| Net margin | -658.6% | -71754.5% | -14678.1% | -20372.3% | -12516.2% | -21936.6% | | -4697.0% |
| |
| Diluted EPS | ($0.10) | ($0.11) | ($0.12) | ($0.13) | ($0.15) | ($0.36) | ($0.21) | ($0.18) |
| Shares outstanding (diluted) | 216.8 | 210.2 | 196.9 | 145.2 | 98.1 | 90.5 | 57.7 | 51.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|